Drug Type CAR-T |
Synonyms anti-CD19 CAR-T therapy, Anti-CD19 chimeric antigen receptor T-cell therapies |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Phase 2 | China | 11 Nov 2018 | |
| B-Cell Lymphoma | Phase 2 | China | - |





